Pharmaceutical compositions comprise nilotinib or a pharmaceutically acceptable salt thereof and a process for the preparation of the same. Methods of using such compositions treat subjects suffering from Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML). A process for preparing dry-granulated pharmaceutical composition of nilotinib comprising compacting nilotinib hydrochloride alone or mixing with one or more of pharmaceutically acceptable excipient(s) by roller compactor or slugging； sizing the compacts or slugs into granules by milling； mixing the granules with one or more of pharmaceutically acceptable excipients to form the composition.
